Cor Vasa 2014, 56(5):582-585 | DOI: 10.33678/cor.2014.052

Dabigatran-etaxilát: Nově schválená indikace léčby a prevence rekurence hluboké žilní trombózy a plicní embolie

Zuzana Zafarová

Published: October 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zafarová Z. Dabigatran-etaxilát: Nově schválená indikace léčby a prevence rekurence hluboké žilní trombózy a plicní embolie. Cor Vasa. 2014;56(5):582-585. doi: 10.33678/cor.2014.052.
Download citation

References

  1. http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm
  2. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, et al., Dabigatran versus warfarin in patients with atrial fibrillation, New England Journal of Medicine 361 (2009) 1139-1151. Go to original source... Go to PubMed...
  3. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, et al., Newly identified events in the RE-LY trial, New England Journal of Medicine 363 (2010) 1875-1876. Go to original source... Go to PubMed...
  4. Pradaxa®: EU SPC, 2014.
  5. S. Schulman, A.K. Kakkar, S.Z. Goldhaber, et al., Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation 129 (2014) 764-772. Go to original source... Go to PubMed...
  6. S. Schulman, C. Kearon, A.K. Kakkar, et al., Extended use of dabigatran, warfarin, or placebo in venous thromboembolism, New England Journal of Medicine 368 (2013) 709-718. Go to original source... Go to PubMed...
  7. S. Schulman, et al., Abstract 1136. Presented at ASH 2013.




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.